Co-investing in the Series A funding are Latterell Venture Partners of San Francisco, California, VantagePoint Venture Partners of San Bruno, California and Adams Street Partners of Chicago, Illinois.
James Woody of Latterell, Annette Bianchi of VantagePoint and Terry Gould of Adams Street will join the Neuraltus board of directors.
The Series A funding will enable Neuraltus to conduct and complete Phase I and Phase II clinical trials for amyotropic lateral sclerosis, Parkinson’s disease and Gaucher’s disease.
Ari Azhir, CEO and co-founder of Neuraltus, said: “It is a great vote of confidence when investors with so much experience in biotechnology have chosen to devote their resources to Neuraltus.”